


Rev. 11/98



RECEIVED

AUG 8 2000

TECH CENTER 1600/2900

Docket No. STK-6

1614

PHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1614  
Applicants : Ugo Ripamonti, et al.  
Serial No. : 09/540,466  
Filed : March 31, 2000  
For : METHODS FOR INDUCING ANGIOGENESIS  
USING MORPHOGENIC PROTEINS AND  
STIMULATORY FACTORS

RECEIVED

AUG 07 2000

TECH CENTER 1600/2900

New York, New York  
July 28, 2000

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information  
Disclosure Statement in the above-identified application.  
This Statement is submitted:

☐ within three months of the application filing  
date;

☒ more than three months from the application  
filing date but before the mailing date of the  
first Office Action on the merits.

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

*Karen Mangasarian*

James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
~~Karen Mangasarian (Reg. No. 43,772)~~  
~~1251 Avenue of the Americas~~  
New York, New York 10020-1104  
Tel.: (212) 596-9000

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to: ASSISTANT  
COMMISSIONER FOR  
PATENTS  
WASHINGTON, D.C. 20231 on

*July 29, 2000*  
Claire J. [unclear]

*[Signature]*  
Signature of Person Signing



STK-6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1614  
Applicants : Ugo Ripamonti, et al.  
Serial No. : 09/540,466  
Filed : March 31, 2000  
For : METHODS FOR INDUCING ANGIOGENESIS  
USING MORPHOGENIC PROTEINS AND  
STIMULATORY FACTORS

New York, New York  
July 28, 2000

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below (copies enclosed herewith). A completed Form PTO-1449 listing all of the documents is enclosed herewith.

Applicants respectfully request that the documents listed below be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

#### United States Patents

<u>Inventor</u>	<u>Serial No.</u>	<u>Issue Date</u>
Oppermann et al.	5,011,691	April 30, 1991
Hunziker	5,270,300	December 14, 1993
Oppermann et al.	5,324,819	June 28, 1994
Oppermann et al.	5,354,557	October 11, 1994
Wolfman et al.	5,399,677	March 21, 1995
Grinna et al.	5,411,941	May 2, 1995
Lee	5,686,425	November 11, 1997
Isner et al.	5,980,887	November 9, 1999
Goldberg et al.	6,013,624	Jan 11, 2000

#### Foreign Patent Publications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Genetics Institute, Inc.	WO93/09229	May 13, 1993
Genetics Institute, Inc.	WO95/05846	March 2, 1995

#### Other Documents

Alini, et al., A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation, Dev. Biol., 176, pp. 124-133 (1996).

Battegay, Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects, J. Mol. Med., 73, pp. 333-346 (1995).

Bussolini, et al., Molecular mechanisms of blood vessel formation, Trends Biochem. Sci., 22, pp. 251-256 (1997).

Duneas, et al., Transforming growth factor - $\beta$ 1: induction of bone morphogenetic protein genes expression during endochondral bone formation in the baboon, and synergistic interaction with osteogenic protein-1 (BMP-7), Growth Factors, 15, pp. 259-277 (1998).

Folkman, Angiogenesis: initiation and control, Ann. NY Acad. Sci., 401, pp. 212-227 (1982).

Folkman and Klagsbrun, Angiogenic factors, Science, 235, pp. 442-447 (1987).

Gerber ,et al., VEGF couples hypertrophic cartilage remodelling, ossification, and angiogenesis during endochondral bone formation, Nat. Med., 5, pp. 623-628 (1999).

Glowacki, Angiogenesis in fracture repair, Clin. Orthop., 355, pp. S82-S89 (1998).

Hanada, et al., Stimulatory effects of basic Fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells, J. Bone and Mineral Res., 12, pp. 1606-1614 (1997).

Hayek, et al., An in vivo model for studying the angiogenic effects of basic fibroblast growth factor, Biochem. Biophys. Res. Commun., 147, pp. 876-880 (1987).

Isner, et al., Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization, J. Clin. Invest., 103, pp. 1231-1236 (1999).

Liem, et al., Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm, Cell, 82, pp. 967-979 (1995).

Ripamonti, et al., Recombinant transforming growth factor  $\beta$ 1 induces endochondral bone in the baboon and synergized with recombinant OP-1 to initiate rapid bone formation, J. Bone and Mineral Res., 12, pp. 1584-1595 (1997).

Si, et al., Induction of new bone by ceramic bovine bone with recombinant human bone morphogenetic protein 2 and transforming growth factor, International J. Oral Maxillofacial Surgery, 27, pp. 310-314 (1998).

Yamashita, et al., Growth/differentiation factor-5 induces angiogenesis in vivo, Exp. Cell. Res., 235, pp. 218-226 (1997).

Yancopoulos, et al., Vasculogenesis, angiogenesis and growth factors: ephrins enter the fray at the border, Cell, 93, pp. 661-664 (1998).

Zagzag, Angiogenic growth factors in neural embryogenesis and neoplasia, Am. J. Pathol., 146, pp. 293-309 (1995).

Zimrin and Maciag, Progress towards a unifying hypothesis for angiogenesis, J. Clin. Invest., 97, p. 1359 (1996).

This Statement is submitted more than three months from the application filing date but before the mailing date of the first substantive Office Action. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Commissioner, however, is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Karen Mangasarian (Reg. No. 43,772)  
Agent for Applicants  
c/o FISH AND NEAVE  
1251 Avenue of the Americas  
New York, New York 10020  
Telephone: (212) 596-9000

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Patent Service as First  
Class Mail in an Envelope  
Addressed to: ASSISTANT  
COMMISSIONER FOR  
PATENTS  
WASHINGTON, D.C. 20231 on

Claire

Initial

July 28, 2001

Signature of person signing